Alpha-Lipoic Acid (ALA): The Antioxidant Your Body Makes — and When to Supplement
Alpha-lipoic acid (ALA) is one of the more interesting compounds in the supplement world because it straddles the line between nutrient and pharmaceutical. Your body produces it naturally, it is found in food, and it has been studied in clinical settings for specific medical conditions. But the wellness industry has also stretched its claims well beyond what the evidence supports.
Here is what ALA actually does, who it might help, and where the hype outpaces the science.
TL;DR
- ALA is a naturally occurring antioxidant that works in both water-soluble and fat-soluble environments — unusual among antioxidants
- The strongest evidence is for diabetic neuropathy at doses of 600 mg/day (Ziegler et al., 2006)
- It may modestly improve insulin sensitivity, but it is not a diabetes treatment on its own
- The body produces ALA naturally; supplementation adds to what you already make
- Common doses range from 300–600 mg/day; higher doses can cause nausea
- Not a magic "anti-aging" pill — temper expectations
What Is Alpha-Lipoic Acid?
ALA is a sulfur-containing compound synthesized in the mitochondria of every human cell. It functions as a cofactor for several mitochondrial enzyme complexes involved in energy metabolism, particularly pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase (Packer et al., 2001).
What makes ALA unusual is its amphipathic nature — it is soluble in both water and fat. Most antioxidants work in one environment or the other (vitamin C in water, vitamin E in fat). ALA crosses both, which gives it a broader theoretical range of action.
When taken as a supplement, ALA is rapidly absorbed and converted to dihydrolipoic acid (DHLA), which is also an antioxidant. Together, the ALA/DHLA pair can regenerate other antioxidants, including vitamins C and E, and glutathione (Biewenga et al., 1997).
What the Evidence Supports
Diabetic Peripheral Neuropathy (Best Evidence)
This is the area with the most clinical data. The NATHAN 1 trial (Ziegler et al., 2006) and the SYDNEY trial (Ametov et al., 2003) both demonstrated that 600 mg/day of intravenous ALA improved neuropathic symptoms — pain, burning, numbness — in patients with diabetic neuropathy.
Oral ALA at 600 mg/day also showed benefits in the SYDNEY 2 trial, though the effects were more modest than intravenous administration (Ziegler et al., 2006). In Germany, ALA has been used for decades as an approved treatment for diabetic neuropathy.
Important nuance: ALA does not cure neuropathy. It reduces symptoms. And the evidence is strongest at 600 mg/day — lower doses show inconsistent results.
Insulin Sensitivity (Moderate Evidence)
Several small studies suggest ALA may improve insulin sensitivity. A meta-analysis by Akbari et al. (2018) found that ALA supplementation significantly reduced fasting glucose and HbA1c in diabetic patients. However, effect sizes were small, and ALA should not be considered a substitute for medication or lifestyle changes.
The mechanism likely involves ALA's activation of AMPK (AMP-activated protein kinase), a cellular energy sensor that also mediates some effects of exercise and metformin (Lee et al., 2005).
Weight Loss (Weak Evidence)
A meta-analysis by Kucukgoncu et al. (2017) found that ALA supplementation was associated with a statistically significant but clinically modest weight loss — about 1.27 kg more than placebo. This is not meaningful weight loss for most people and should not be a primary reason to supplement.
Antioxidant and Anti-Inflammatory Effects (Theoretical)
ALA's ability to regenerate other antioxidants and reduce markers of oxidative stress has been demonstrated in laboratory settings (Packer et al., 2001). Whether this translates to meaningful clinical benefits in healthy people taking oral supplements is less clear. The body already makes ALA, and adding more may not substantially change oxidative status in someone without a specific deficiency or condition.
Who Might Benefit?
| Profile | Evidence | Notes |
|---|---|---|
| Diabetic neuropathy patients | Strong | 600 mg/day, ideally under medical supervision |
| Type 2 diabetes (adjunct therapy) | Moderate | May modestly improve glucose markers |
| Overweight individuals | Weak | ~1 kg additional loss, not clinically significant |
| Healthy adults "for antioxidants" | Insufficient | No evidence of benefit beyond normal production |
| Athletes for recovery | Limited | Some animal data, no strong human trials |
Forms and Dosing
ALA supplements come in two forms:
- R-lipoic acid (R-ALA): The naturally occurring form. More bioavailable but less stable and more expensive.
- Racemic ALA (R/S-ALA): A 50/50 mix of R and S forms. Most clinical trials used this form. Cheaper and well-studied.
Typical doses:
- General supplementation: 300–600 mg/day
- Diabetic neuropathy (clinical): 600 mg/day
- Higher doses (1,200+ mg) are occasionally used in research but increase risk of nausea and GI discomfort
Take ALA on an empty stomach for better absorption — food reduces bioavailability by about 30% (Teichert et al., 2003).
Common Mistakes
1. Expecting dramatic antioxidant effects in healthy people. Your body already makes ALA. Supplementing adds to the pool, but healthy individuals may not notice measurable benefits.
2. Using ALA as a diabetes treatment without medical supervision. ALA can lower blood sugar. Combined with diabetes medications, this could cause hypoglycemia. Always inform your doctor.
3. Choosing the wrong form based on marketing. R-ALA is marketed as "natural" and "superior," but most clinical evidence comes from racemic ALA. Both work; do not overpay for unproven superiority.
4. Taking high doses without working up gradually. Start at 300 mg and increase to 600 mg if tolerated. Nausea is the most common side effect at higher doses.
5. Confusing alpha-lipoic acid with alpha-linolenic acid. Both are abbreviated "ALA" in different contexts. Alpha-linolenic acid is an omega-3 fatty acid — completely different compound.
Estonia-Specific Notes
ALA supplements are available in Estonian pharmacies and online stores. Most products use racemic ALA at 300–600 mg per capsule, with prices ranging from €8–18 for a month's supply.
In Estonia, diabetes prevalence has been increasing, mirroring broader European trends. If you are considering ALA for diabetes-related reasons, consult with your endocrinologist — several Estonian endocrinology clinics are familiar with ALA's evidence base.
MaxFit.ee carries alpha-lipoic acid supplements with clear dosing information per capsule.
FAQ
Is alpha-lipoic acid safe?
At 300–600 mg/day, ALA is generally well-tolerated. The most common side effects are nausea and mild GI discomfort. EFSA has not set a formal upper limit, but doses above 1,200 mg/day significantly increase side effects (Ziegler et al., 2006).
Can ALA replace diabetes medication?
No. ALA may modestly improve insulin sensitivity (Akbari et al., 2018), but it is not a substitute for prescribed medications like metformin or insulin. Treat it as a potential adjunct, not a replacement.
Should I take R-ALA or regular ALA?
Most clinical trials used racemic (R/S) ALA. R-ALA has higher bioavailability per milligram, but there is no strong evidence it produces better clinical outcomes. Racemic ALA is cheaper and well-validated.
Does ALA help with anti-aging?
The theoretical basis exists — ALA reduces oxidative stress markers in lab settings (Packer et al., 2001). But no human clinical trials demonstrate that ALA supplementation slows aging or produces meaningful anti-aging outcomes. Do not supplement for this reason alone.
Can I get enough ALA from food?
ALA is found in organ meats (liver, kidney), spinach, broccoli, and tomatoes, but in very small amounts — typically 1–2 mg per serving (Lodge et al., 1997). Supplemental doses (300–600 mg) are 150–600x higher than dietary intake. Food sources are not a realistic alternative if you need therapeutic doses.
References
- Akbari, M. et al. (2018). The effects of alpha-lipoic acid supplementation on glucose control and lipid profiles among patients with metabolic diseases: A systematic review and meta-analysis. Metabolism, 87, 56–69.
- Ametov, A.S. et al. (2003). The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care, 26(3), 770–776.
- Biewenga, G.P. et al. (1997). The pharmacology of the antioxidant lipoic acid. General Pharmacology, 29(3), 315–331.
- Kucukgoncu, S. et al. (2017). Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials. Obesity Reviews, 18(5), 594–601.
- Lee, W.J. et al. (2005). Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochemical and Biophysical Research Communications, 332(3), 885–891.
- Lodge, J.K. et al. (1997). Natural sources of lipoic acid: determination of lipoyllysine released from protease-digested tissues by high performance liquid chromatography. Journal of Applied Nutrition, 49, 3–11.
- Packer, L. et al. (2001). Alpha-lipoic acid as a biological antioxidant. Free Radical Biology and Medicine, 19(2), 227–250.
- Teichert, J. et al. (2003). Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics, 41(12), 521–526.
- Ziegler, D. et al. (2006). Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care, 29(11), 2365–2370.
See also:
